Search clinical trials for: Kisspeptin 112-121

Total 4864 results

SciClone Pharmaceuticals

Unknown

An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma

Advanced Solid Tumors

China
TaiwanJ Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis

Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (Maui)

Blepharitis

United States
David Bushnell
VA Office of Research and Development

Completed

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Imperial College London

Recruiting

Reproductive Hormones During Sustained Administration of Kisspeptin (KisspeptPump)

Fertility Disorders | Hypothalamic Dysfunction

United Kingdom
Stephanie B. Seminara, MD

Recruiting

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

Pregnancy | Healthy Volunteers | Insulin | Glucose | Women

United States
Nguyen Thi Trieu, MD

Completed

Composition for Treating Cirrhosis and Liver Cancer (SB-1121) (SB-1121)

Cirrhosis of the Liver

Vietnam
Qlaris Bio, Inc.

Recruiting

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Glaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)

United States
University of North Carolina, Chapel Hill
Boston Children's Hospital; Medical College of Wisconsin; National Football League

Enrolling by invitation

NFL LONG Prospective Study

Concussion, Brain

United States
Precision Life Sciences Group

Completed

A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma

Glioblastoma Multiforme

United States
Highlight Therapeutics
Pivotal S.L.

Completed

Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors

Cancer

Spain
Celgene

Completed

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

France, Italy, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Hamamatsu University
Japan Agency for Medical Research and Development

Unknown

A Trial of TTA-121 on Autism Spectrum Disorder

Autism Spectrum Disorder

Japan
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Sensorion

Completed

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Acute Unilateral Vestibulopathy (AUV)

United States, Israel, France, Korea, Republic of, Hungary, Germany, Czechia, Italy
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (STRIDE 2)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Tarapeutics Science Inc.

Recruiting

A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
REGENXBIO Inc.

Active, not recruiting

RGX-111 Gene Therapy in Patients With MPS I

Hurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)

United States, Brazil, Israel
Kala Pharmaceuticals, Inc.

Completed

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (Molokini)

Diabetic Macular Edema | Retinal Vein Occlusion

United States
Scioto Biosciences, Inc.

Completed

28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder

Autistic Disorder

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (STRIDE 1)

Dry Eye Syndromes | Keratoconjunctivitis Sicca

United States
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
argenx

Completed

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Cancer

Belgium
Vascular Biogenics Ltd. operating as VBL Therapeutics

Unknown

A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Advanced and/or Metastatic Solid Organ Cancer

United States
Metastatix, Inc.

Suspended

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

Solid Tumors

United States
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Auris Medical AG

Completed

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

Hearing Loss

Bulgaria
Mallinckrodt

Terminated

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

Solid Tumors

United States
Sanofi
Merrimack Pharmaceuticals

Completed

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

Solid Tumor Cancers

United States
TaiwanJ Pharmaceuticals Co., Ltd

Terminated

Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies (JKB122)

Chronic Hepatitis C

Taiwan
Protalix

Completed

Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

Gaucher Disease

Israel
Veru Inc.

Terminated

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Auris Medical AG

Completed

Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss

Hearing Loss

Germany
Icosavax, Inc.

Completed

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Healthy

United States
Georgiamune Inc

Recruiting

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Veru Inc.

Completed

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study (VERU-111)

SARS-CoV Infection

United States, Argentina, Brazil, Bulgaria, Colombia, Mexico
Oncostellae S.L

Completed

Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe

Spain, Ukraine
Veru Inc.

Completed

COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111

Respiratory Distress Syndrome, Adult

United States
KeifeRx, LLC
Worldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...

Not yet recruiting

Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease (NILEAD)

Alzheimer Disease
Protalix

Completed

An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

Gaucher Disease

Israel

Search clinical trials for: Kisspeptin 112-121

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations